We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+8.42%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$80B
AUM Growth
+$5.37B
Cap. Flow
-$213M
Cap. Flow %
-0.27%
Top 10 Hldgs %
23.95%
Holding
3,773
New
259
Increased
1,520
Reduced
1,671
Closed
192

Sector Composition

Rank Sector Weight
1 Technology 14.33%
2 Healthcare 8.9%
3 Financials 7.71%
4 Consumer Discretionary 6.92%
5 Industrials 6.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KRG icon
2726
Kite Realty
KRG
$5.31B
$415K ﹤0.01%
35,811
-3,973
-10% -$43.7K
PAG icon
2727
Penske Automotive Group
PAG
$14.4B
$415K ﹤0.01%
8,703
+1,827
+27% +$84.8K
BMY.RT
2728
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$414K ﹤0.01%
183,881
-599,569
-77% -$1.71M
CXH
2729
DELISTED
MFS Investment Grade Municipal Trust
CXH
$413K ﹤0.01%
43,958
-20,806
-32% -$201K
DAN icon
2730
Dana Inc
DAN
$3.26B
$413K ﹤0.01%
33,492
-700
-2% -$9.1K
IFN
2731
Aberdeen India Fund
IFN
$505M
$413K ﹤0.01%
25,006
-2,255
-8% -$37K
LNW
2732
DELISTED
Light & Wonder
LNW
$413K ﹤0.01%
+11,839
New +$254K
EMO
2733
ClearBridge Energy Midstream Opportunity Fund
EMO
$1.06B
$412K ﹤0.01%
46,973
+7,495
+19% +$82.6K
FAB icon
2734
First Trust Multi Cap Value AlphaDEX Fund
FAB
$178M
$412K ﹤0.01%
8,872
-440
-5% -$21K
PROF
2735
Profound Medical
PROF
$242M
$412K ﹤0.01%
+23,421
New +$372K
NXJ
2736
DELISTED
Nuveen New Jersey Quality Municipal Income Fund
NXJ
$410K ﹤0.01%
30,300
+35
+0.1% +$479
QURE icon
2737
uniQure
QURE
$3.26B
$410K ﹤0.01%
11,138
+4,596
+70% +$188K
NVRO
2738
DELISTED
NEVRO CORP.
NVRO
$409K ﹤0.01%
2,935
+3
+0.1% +$401
NMT icon
2739
Nuveen Massachusetts Quality Municipal Income Fund
NMT
$130M
$408K ﹤0.01%
29,100
PI icon
2740
Impinj
PI
$5.46B
$408K ﹤0.01%
15,468
+993
+7% +$26.2K
SCL icon
2741
Stepan Co
SCL
$1.48B
$408K ﹤0.01%
3,746
+569
+18% +$62.3K
BBVA icon
2742
Banco Bilbao Vizcaya Argentaria
BBVA
$158B
$407K ﹤0.01%
148,554
+46,731
+46% +$145K
CSTM icon
2743
Constellium
CSTM
$3.95B
$406K ﹤0.01%
51,636
-1,286
-2% -$10.6K
PARR icon
2744
Par Pacific Holdings
PARR
$4.12B
$406K ﹤0.01%
+60,000
New +$497K
STAA icon
2745
STAAR Surgical
STAA
$1.26B
$405K ﹤0.01%
+7,156
New +$385K
DRNA
2746
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$405K ﹤0.01%
22,495
+17
+0.1% +$352
GIS icon
2747
CALL
General Mills
GIS
$20.8B
$404K ﹤0.01%
67,700
+200
+0.3% +$12.5K
WHD icon
2748
Cactus
WHD
$5.78B
$404K ﹤0.01%
21,061
+866
+4% +$18.8K
SJR
2749
DELISTED
Shaw Communications Inc.
SJR
$403K ﹤0.01%
22,067
+3,377
+18% +$61.6K
DLX icon
2750
Deluxe
DLX
$1.11B
$402K ﹤0.01%
15,637
+162
+1% +$4.18K

Similar funds

Raymond James & Associates's Q3 2020 Portfolio in Review

As of Q3 2020, Raymond James & Associates held 3,773 positions worth $80B, up 7.2% from $74.6B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Raymond James & Associates's Q3 2020 filing shows 259 new, 1,520 increased, 1,671 reduced and 192 closed positions. Its largest new stake was Rocket Companies: 405,835 shares worth $8.09M. The largest sale was Apple, an estimated $134M.

By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

  • Raymond James & Associates's largest Q3 2020 buy was Rocket Companies: 405,835 shares worth $8.09M.
  • Raymond James & Associates added most to iShares Core US Aggregate Bond ETF in Q3 2020, an estimated $140M increase.
  • Raymond James & Associates's biggest Q3 2020 reduction was Apple, cutting an estimated $134M.
  • Raymond James & Associates fully exited Invesco Russell 1000 Dynamic Multifactor ETF in Q3 2020, selling an estimated $15.9M.
  • Raymond James & Associates's ten largest holdings make up 24% of its $80B portfolio in Q3 2020.
  • Raymond James & Associates opened 259 new positions and closed 192 in Q3 2020.
  • Raymond James & Associates's portfolio value rose 7.2% quarter-over-quarter to $80B.

Based on Raymond James & Associates's 13F filing for Q3 2020, filed 4 Nov 2020.